<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714970</url>
  </required_header>
  <id_info>
    <org_study_id>WU2021TMS</org_study_id>
    <nct_id>NCT04714970</nct_id>
  </id_info>
  <brief_title>rTMS on Appetite and Cognitive Function in Schizophrenia</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation on Appetite and Cognitive Function in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The weight gain and metabolic dysfunction has been vital conditions for individuals with&#xD;
      schizophrenia. rTMS is a promising novel intervention, which have strong potentials on&#xD;
      moderating increased appetite and cognitive deficits in schizophrenia, as it has been proved&#xD;
      for the treatment of depression.&#xD;
&#xD;
      Therefore, the investigators designed this randomized controlled clinical trial to evaluate&#xD;
      the efficacy and safety of rTMS, using iTBS pattern, on prevention and treatment for elevated&#xD;
      appetite and cognitive deficiency in individual with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The weight gain and metabolic dysfunction has been vital conditions for individuals with&#xD;
      schizophrenia. The cognitive function deficit has also been a major symptom for&#xD;
      schizophrenia. However, metabolic dysfunction could further impair the cognition. rTMS is a&#xD;
      promising novel intervention, which have strong potentials on moderating increased appetite&#xD;
      and cognitive deficits in schizophrenia, as it has been proved for the treatment of&#xD;
      depression.&#xD;
&#xD;
      Therefore, the investigators designed this randomized controlled clinical trial to evaluate&#xD;
      the efficacy and safety of rTMS, using iTBS pattern, on prevention of the elevated appetite&#xD;
      and cognitive deficiency in individual with schizophrenia. The intervention will last for 5&#xD;
      continuous days and the follow-ups are scheduled at baseline, 6days and 36days. The primary&#xD;
      outcomes include the change of MCCB score, TFEQ score and EEG data. Secondary outcomes&#xD;
      include the change of serum metabolic indexes and anthropometry indexes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>60 participants are randomized, through the predetermined random number list, into intervention group or sham stimulation group in equal.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Appetite</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>Three-Factor Eating Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of MCCB</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>The MATRICSâ„¢ Consensus Cognitive Battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of ERP</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>Food picture ERP recorded by EEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of fasting glucose</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fasting insulin level</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Triglyceride</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Total Cholesterol</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LDL</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HDL</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BMI</measure>
    <time_frame>Change from Baseline to 6days and 36days</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>iTBS stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants randomized into experimental group will receive iTBS stimulation of dlPFC 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The participants randomized intoSham group will receive Sham stimulation, as the coil vertical to the brain surface, 5 times a day, with 1h interval between two stimulations, and for 5 continuous days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTBS</intervention_name>
    <description>Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.</description>
    <arm_group_label>iTBS stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shame stimulation</intervention_name>
    <description>TMS coil vertical to the brain surface, with same protocol as iTBS</description>
    <arm_group_label>Sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with schizophrenia in accordance with DSM-5&#xD;
&#xD;
          -  Commorbid with significant weight gain after antipsychotics&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with other mental disease in accordance with DSM-5&#xD;
&#xD;
          -  Comorbid with other severe physiological disease&#xD;
&#xD;
          -  Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances&#xD;
             before&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Contraindication to rTMS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renrong Wu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University Psychiatry Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renrong Wu, Prof</last_name>
    <phone>15874179855</phone>
    <email>wurenrong@csu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renrong Wu, Prof</last_name>
      <phone>+86 158 741 79855</phone>
      <email>wurenrong@csu.edu</email>
    </contact>
    <investigator>
      <last_name>Renrong Wu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongyu Kang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuhan Song, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Renrong Wu,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>rTMS</keyword>
  <keyword>Appetite</keyword>
  <keyword>Cognitive Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

